[HTML][HTML] Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and adaptive immunity through …
Immunoglobulin (Ig) G1 antibodies stimulate antibody-dependent cell-mediated cytotoxicity
(ADCC). Cetuximab, an IgG1 isotype monoclonal antibody, is a standard-of-care treatment …
(ADCC). Cetuximab, an IgG1 isotype monoclonal antibody, is a standard-of-care treatment …
[HTML][HTML] Evidence-based treatment options in recurrent and/or metastatic squamous cell carcinoma of the head and neck
A Argiris, KJ Harrington, M Tahara, J Schulten… - Frontiers in …, 2017 - frontiersin.org
The major development of the past decade in the first-line treatment of recurrent and/or
metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) was the …
metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) was the …
[HTML][HTML] Clinical update on cancer: molecular oncology of head and neck cancer
Head and neck cancers encompass a heterogeneous group of tumours that, in general, are
biologically aggressive in nature. These cancers remain difficult to treat and treatment can …
biologically aggressive in nature. These cancers remain difficult to treat and treatment can …
Lung cancer biomarkers: present status and future developments
PT Cagle, TC Allen, RJ Olsen - Archives of Pathology …, 2013 - meridian.allenpress.com
The publication of the “Molecular Testing Guideline for Selection of Lung Cancer Patients for
EGFR and ALK Tyrosine Kinase Inhibitors: Guideline From the College of American …
EGFR and ALK Tyrosine Kinase Inhibitors: Guideline From the College of American …
Design of a phase I clinical trial to evaluate intratumoral delivery of ErbB-targeted chimeric antigen receptor T-cells in locally advanced or recurrent head and neck …
MCI van Schalkwyk, SE Papa, JP Jeannon… - Human gene therapy …, 2013 - liebertpub.com
Despite several advances, 5-year survival in patients with head and neck squamous cell
carcinoma (HNSCC) remains unchanged at only 50%. The commonest cause of death is …
carcinoma (HNSCC) remains unchanged at only 50%. The commonest cause of death is …
[HTML][HTML] In Vivo Fluorescence Immunohistochemistry: Localization of Fluorescently Labeled Cetuximab in Squamous Cell Carcinomas
Anti-EGFR (epidermal growth factor receptor) antibody based treatment strategies have
been successfully implemented in head and neck squamous cell carcinoma (HNSCC) …
been successfully implemented in head and neck squamous cell carcinoma (HNSCC) …
Diffusion-weighted imaging in head and neck cancers
S Chawla, S Kim, S Wang, H Poptani - Future oncology, 2009 - Future Medicine
This article reviews the utility of diffusion-weighted imaging (DWI) in the diagnosis,
prognosis and monitoring of treatment response in tumors arising in the head and neck …
prognosis and monitoring of treatment response in tumors arising in the head and neck …
New treatment strategies for HPV-positive head and neck cancer
Epidemiological studies show an increasing incidence of human papilloma virus-associated
oropharyngeal cancer. HPV-positive head and neck squamous cell carcinoma (HNSCC) is …
oropharyngeal cancer. HPV-positive head and neck squamous cell carcinoma (HNSCC) is …
[HTML][HTML] Long non-coding RNAs orchestrate various molecular and cellular processes by modulating epithelial-mesenchymal transition in head and neck squamous …
A Sharma, S Kansara, M Mahajan, B Yadav… - … et Biophysica Acta (BBA …, 2021 - Elsevier
Long noncoding RNAs (lncRNAs) regulate various hallmarks associated with the
progression of human cancers through their binding with RNA, DNA, and proteins. Epithelial …
progression of human cancers through their binding with RNA, DNA, and proteins. Epithelial …
[HTML][HTML] A novel intra-tumoral drug delivery carrier for treatment of oral squamous cell carcinoma
SA Elsaady, MN Aboushelib, E Al-Wakeel… - Scientific Reports, 2023 - nature.com
The treatment of oral squamous cell carcinoma (OSCC) includes systemic chemotherapy
and is associated with aggressive side effects on patients. This study evaluated a new intra …
and is associated with aggressive side effects on patients. This study evaluated a new intra …